Top News

RNA strand illustration representing personalised antisense therapy development

INNOVATION

1 Feb 2025

Inside the Push to Personalize RNA Medicine

Tailored antisense drugs move from concept to clinic as researchers and companies test faster models for ultra-rare conditions

BridgeBio Attruby medicine box for transthyretin amyloid cardiomyopathy

INSIGHTS

30 Oct 2025

BridgeBio’s Strategy Shift Tests the Economics of Rare Disease

RESEARCH

20 Sep 2025

From Niche to Notable: Rare Diseases Reshape Biotech

Latest News

INSIGHTS
30 Mar 2026
FDA Bets on Biology Over Bureaucracy
INNOVATION
25 Mar 2026
Stem Cells Step Up for Failing Eyes
MARKET TRENDS
19 Mar 2026
Why Small Molecules Are Back in the Spotlight
INSIGHTS
16 Mar 2026
The $100 Million Voucher Is Back From the Brink

Why Novartis Just Spent $12B on a Tiny Biotech

PARTNERSHIPS

10 Mar 2026

Novartis completes $12B Avidity acquisition, gaining RNA muscle-targeting platform and three rare neuromuscular therapies

INNOVATION

1 Feb 2025

Inside the Push to Personalize RNA Medicine

Tailored antisense drugs move from concept to clinic as researchers and companies test faster models for ultra-rare conditions

3 4

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.